Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm adjuvant ensartinib study in stage IA ALK-positive high-risk lung adenocarcinoma
ChiCTR2500102966Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: 3-year disease-free survival rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500102966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102966.